Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Fosamax with D
Fosamax with D
I cannot find any information about the advantages of taking Fosamax with D.
I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
Is there some advantage to taking it with D that you have read about? I
take my Calcium with D, and I am trying to figure out is the only advantage
is convenience, I should not bother. It may not be especially easy to fine
Calcium with Magnisium and no D. Also I cannot even find out how much D is
in the Fosamax.
My doctor said she would be happy to send me a new prescription, but does
not know if there is any advantage to switching.
Sammy
I cannot find any information about the advantages of taking Fosamax with D.
I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
Is there some advantage to taking it with D that you have read about? I
take my Calcium with D, and I am trying to figure out is the only advantage
is convenience, I should not bother. It may not be especially easy to fine
Calcium with Magnisium and no D. Also I cannot even find out how much D is
in the Fosamax.
My doctor said she would be happy to send me a new prescription, but does
not know if there is any advantage to switching.
Sammy
Re: Fosamax with D
Sammy wrote:
: I cannot find any information about the advantages of taking Fosamax
: with D. I have gone to the Merck site, About,com , Webmd, and Cedars
: of Sinai.
:
: Is there some advantage to taking it with D that you have read about?
: I take my Calcium with D, and I am trying to figure out is the only
: advantage is convenience, I should not bother. It may not be
: especially easy to fine Calcium with Magnisium and no D. Also I
: cannot even find out how much D is in the Fosamax.
:
: My doctor said she would be happy to send me a new prescription, but
: does not know if there is any advantage to switching.
:
: Sammy
To my knowledge there is 10 mcg (400 IU) vitamin D per day in the Fosamax
with D dosage. Your vitamin D needs depend on your location and the amount
of sun exposure, but it is very likely that you need more than 10 mcg per
day. Personally I take 40-50 mcg (1600-2000 IU) daily from fall to spring.
If in doubt, get your circulating vitamin D levels assessed.
--
Juhana
Sammy wrote:
: I cannot find any information about the advantages of taking Fosamax
: with D. I have gone to the Merck site, About,com , Webmd, and Cedars
: of Sinai.
:
: Is there some advantage to taking it with D that you have read about?
: I take my Calcium with D, and I am trying to figure out is the only
: advantage is convenience, I should not bother. It may not be
: especially easy to fine Calcium with Magnisium and no D. Also I
: cannot even find out how much D is in the Fosamax.
:
: My doctor said she would be happy to send me a new prescription, but
: does not know if there is any advantage to switching.
:
: Sammy
To my knowledge there is 10 mcg (400 IU) vitamin D per day in the Fosamax
with D dosage. Your vitamin D needs depend on your location and the amount
of sun exposure, but it is very likely that you need more than 10 mcg per
day. Personally I take 40-50 mcg (1600-2000 IU) daily from fall to spring.
If in doubt, get your circulating vitamin D levels assessed.
--
Juhana
Re: Fosamax with D
Sammy wrote:
> I cannot find any information about the advantages of taking Fosamax with D.
> I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>
> Is there some advantage to taking it with D that you have read about? I
> take my Calcium with D, and I am trying to figure out is the only advantage
> is convenience, I should not bother. It may not be especially easy to fine
> Calcium with Magnisium and no D. Also I cannot even find out how much D is
> in the Fosamax.
>
> My doctor said she would be happy to send me a new prescription, but does
> not know if there is any advantage to switching.
>
> Sammy
For people with the fragile bones of osteoporosis, Fosamax and Actonel
were approved by the FDA about 11 years ago. Doctors wrote 22 million
Fosamax prescriptions last year making 3.2 Billion dollars for the drug
maker, Merck. Fosamax reduced fracture rates in the Fracture
Intervention Trial for severe forms of osteoporosis, but for the milder
form of osteoporosis (osteopenia), there was no benefit. These
bisphosphonate drugs work their magic on bones by making the osteoclast
bone cells nonfunctional. Although this allows new bone formation to
proceed normally, the removal of old bone is halted resulting in
increased bone density which shows up on DEXA bone scan.
In spite of this increased bone density, Dr. Susan Ott, Associate
Professor of Medicine, at the University of Washington in Seattle
raised questions about the long term safety of bisphosphonates in her
article in J Clin Endo Metab (Vol. 90, No. 3, 2005) . Although the
drugs appear to have short term benefits, Dr. Ott speculates that after
5 years of use, there is severe suppression of bone formation with
negative effects such as microdamage and brittleness of bone which may
cause spontaneous fractures, an outcome quite the opposite of the
intended use of Fosamax. Dr. Ott suggests stopping the drug within
five years to avoid these adverse side effects.
An example of this adverse side effect is described by Dr.
Jennifer P. Schneider in the Jan 2006 issue of Geriatrics reporting on
a 59-year old previously healthy woman on long-term Fosamax treatment.
One morning, while the woman rode a subway train in New York City, the
train jolted, and the woman shifted all her weight to one leg, felt a
bone snap, fell to the floor with a spontaneous mid-femur fracture. In
the months following, the mid-femur fracture failed to heal. Dr.
Schneider speculates that the increased bone density from the
bisphosphonate drug did not produce good bone quality. Instead she
speculates that long term use of the drug caused microdamage and
brittle bone formation resulting in the spontaneous mid femur fracture.
Dr. Clarita V. Odvina, in the 2005 issue of J Clin Endo & Metab
(Vol. 90, No. 3) reports on 9 patients who had spontanous fractures
while on Fosamax. Five of the nine cases were spontaneous mid femur
fractures with minimal trauma. Dr. Odvina raised the possibility that
long-term Fosamax (alendronate) therapy could result in increased
susceptibility to fractures, quite the opposite of its intended use.
Another bone which shows weakening from bisphosphonates is the jaw bone
which literally falls apart, a term called osteonecrosis. A recent
Library of Medicine Medline search yielded 165 articles on
osteonecrosis of the jaw associated with bisphosphonate use, and most
dentists have by now received warnings about this problem. Dr.
Dimitrakopoulos from the Department of Oral and Maxillofacial Surgery,
Aristotle University of Thessaloniki, Greece. reports in July 2006
issue of Int J Oral Maxillofac Surg. 11 patients presenting with
necrosis of the jaw, and he claims this to be a new complication of
bisphosphonate therapy. He advises physicians to reconsider the merits
of the rampant use of bisphosphonate drugs for osteoporosis.
Osteonecrosis of the jaw is also a common finding in the rare genetic
bone disease called, pycnodysostosis, which is what afflicted Toulouse
Lautrec, the famous French Impressionist artist. By the way, Toulouse
also suffered spontaneous mid femur fractures at the age of 12, just
like the woman on the subway described above. His fractures failed to
heal and Toulouse Lautrec only attained a height of 4 and a half feet.
In conclusion, the bisphosphonate drugs for osteoporosis may have some
short term benefits, however, adverse side effects of spontaneous
fracture and osteonecrosis of the jaw should be mentioned when
considering long term use. For a natural approach to osteoporosis
prevention and treatment without drugs, see my web site:
www .drdach,com .
Jeffrey Dach
Sammy wrote:
> I cannot find any information about the advantages of taking Fosamax with D.
> I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>
> Is there some advantage to taking it with D that you have read about? I
> take my Calcium with D, and I am trying to figure out is the only advantage
> is convenience, I should not bother. It may not be especially easy to fine
> Calcium with Magnisium and no D. Also I cannot even find out how much D is
> in the Fosamax.
>
> My doctor said she would be happy to send me a new prescription, but does
> not know if there is any advantage to switching.
>
> Sammy
For people with the fragile bones of osteoporosis, Fosamax and Actonel
were approved by the FDA about 11 years ago. Doctors wrote 22 million
Fosamax prescriptions last year making 3.2 Billion dollars for the drug
maker, Merck. Fosamax reduced fracture rates in the Fracture
Intervention Trial for severe forms of osteoporosis, but for the milder
form of osteoporosis (osteopenia), there was no benefit. These
bisphosphonate drugs work their magic on bones by making the osteoclast
bone cells nonfunctional. Although this allows new bone formation to
proceed normally, the removal of old bone is halted resulting in
increased bone density which shows up on DEXA bone scan.
In spite of this increased bone density, Dr. Susan Ott, Associate
Professor of Medicine, at the University of Washington in Seattle
raised questions about the long term safety of bisphosphonates in her
article in J Clin Endo Metab (Vol. 90, No. 3, 2005) . Although the
drugs appear to have short term benefits, Dr. Ott speculates that after
5 years of use, there is severe suppression of bone formation with
negative effects such as microdamage and brittleness of bone which may
cause spontaneous fractures, an outcome quite the opposite of the
intended use of Fosamax. Dr. Ott suggests stopping the drug within
five years to avoid these adverse side effects.
An example of this adverse side effect is described by Dr.
Jennifer P. Schneider in the Jan 2006 issue of Geriatrics reporting on
a 59-year old previously healthy woman on long-term Fosamax treatment.
One morning, while the woman rode a subway train in New York City, the
train jolted, and the woman shifted all her weight to one leg, felt a
bone snap, fell to the floor with a spontaneous mid-femur fracture. In
the months following, the mid-femur fracture failed to heal. Dr.
Schneider speculates that the increased bone density from the
bisphosphonate drug did not produce good bone quality. Instead she
speculates that long term use of the drug caused microdamage and
brittle bone formation resulting in the spontaneous mid femur fracture.
Dr. Clarita V. Odvina, in the 2005 issue of J Clin Endo & Metab
(Vol. 90, No. 3) reports on 9 patients who had spontanous fractures
while on Fosamax. Five of the nine cases were spontaneous mid femur
fractures with minimal trauma. Dr. Odvina raised the possibility that
long-term Fosamax (alendronate) therapy could result in increased
susceptibility to fractures, quite the opposite of its intended use.
Another bone which shows weakening from bisphosphonates is the jaw bone
which literally falls apart, a term called osteonecrosis. A recent
Library of Medicine Medline search yielded 165 articles on
osteonecrosis of the jaw associated with bisphosphonate use, and most
dentists have by now received warnings about this problem. Dr.
Dimitrakopoulos from the Department of Oral and Maxillofacial Surgery,
Aristotle University of Thessaloniki, Greece. reports in July 2006
issue of Int J Oral Maxillofac Surg. 11 patients presenting with
necrosis of the jaw, and he claims this to be a new complication of
bisphosphonate therapy. He advises physicians to reconsider the merits
of the rampant use of bisphosphonate drugs for osteoporosis.
Osteonecrosis of the jaw is also a common finding in the rare genetic
bone disease called, pycnodysostosis, which is what afflicted Toulouse
Lautrec, the famous French Impressionist artist. By the way, Toulouse
also suffered spontaneous mid femur fractures at the age of 12, just
like the woman on the subway described above. His fractures failed to
heal and Toulouse Lautrec only attained a height of 4 and a half feet.
In conclusion, the bisphosphonate drugs for osteoporosis may have some
short term benefits, however, adverse side effects of spontaneous
fracture and osteonecrosis of the jaw should be mentioned when
considering long term use. For a natural approach to osteoporosis
prevention and treatment without drugs, see my web site:
www .drdach,com .
Jeffrey Dach
Re: Fosamax with D
Hi Sammy: I thought Merck did this for convenience, but I would confirm that
with your dr or pharmacist. Fosamax plus D has 2,800 IU of D3 so it represents
a weeks worth of D at 400 IU's daily. I suppose it would be up to you or your
dr which way of taking it is easier, daily or weekly. You do need to know if
you are taking anything, or have a disorder that would deplete your system of D,
and a pharmacist could give you a list of those drugs/disorders, or it should be
listed on the Merck website. Also some feel that 400 daily IU's isn't enough D
for certain age groups so you could ask about that as well.
Pam
"keyboard" <keyboard@anonymousSpeech,com > wrote in message
news:1166737952.097865.8380@i12g2000cwa.googlegroups,com ...
>
> Sammy wrote:
>> I cannot find any information about the advantages of taking Fosamax with D.
>> I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>>
>> Is there some advantage to taking it with D that you have read about? I
>> take my Calcium with D, and I am trying to figure out is the only advantage
>> is convenience, I should not bother. It may not be especially easy to fine
>> Calcium with Magnisium and no D. Also I cannot even find out how much D is
>> in the Fosamax.
>>
>> My doctor said she would be happy to send me a new prescription, but does
>> not know if there is any advantage to switching.
>>
>> Sammy
>
> For people with the fragile bones of osteoporosis, Fosamax and Actonel
> were approved by the FDA about 11 years ago. Doctors wrote 22 million
> Fosamax prescriptions last year making 3.2 Billion dollars for the drug
> maker, Merck. Fosamax reduced fracture rates in the Fracture
> Intervention Trial for severe forms of osteoporosis, but for the milder
> form of osteoporosis (osteopenia), there was no benefit. These
> bisphosphonate drugs work their magic on bones by making the osteoclast
> bone cells nonfunctional. Although this allows new bone formation to
> proceed normally, the removal of old bone is halted resulting in
> increased bone density which shows up on DEXA bone scan.
>
> In spite of this increased bone density, Dr. Susan Ott, Associate
> Professor of Medicine, at the University of Washington in Seattle
> raised questions about the long term safety of bisphosphonates in her
> article in J Clin Endo Metab (Vol. 90, No. 3, 2005) . Although the
> drugs appear to have short term benefits, Dr. Ott speculates that after
> 5 years of use, there is severe suppression of bone formation with
> negative effects such as microdamage and brittleness of bone which may
> cause spontaneous fractures, an outcome quite the opposite of the
> intended use of Fosamax. Dr. Ott suggests stopping the drug within
> five years to avoid these adverse side effects.
>
> An example of this adverse side effect is described by Dr.
> Jennifer P. Schneider in the Jan 2006 issue of Geriatrics reporting on
> a 59-year old previously healthy woman on long-term Fosamax treatment.
> One morning, while the woman rode a subway train in New York City, the
> train jolted, and the woman shifted all her weight to one leg, felt a
> bone snap, fell to the floor with a spontaneous mid-femur fracture. In
> the months following, the mid-femur fracture failed to heal. Dr.
> Schneider speculates that the increased bone density from the
> bisphosphonate drug did not produce good bone quality. Instead she
> speculates that long term use of the drug caused microdamage and
> brittle bone formation resulting in the spontaneous mid femur fracture.
>
> Dr. Clarita V. Odvina, in the 2005 issue of J Clin Endo & Metab
> (Vol. 90, No. 3) reports on 9 patients who had spontanous fractures
> while on Fosamax. Five of the nine cases were spontaneous mid femur
> fractures with minimal trauma. Dr. Odvina raised the possibility that
> long-term Fosamax (alendronate) therapy could result in increased
> susceptibility to fractures, quite the opposite of its intended use.
>
> Another bone which shows weakening from bisphosphonates is the jaw bone
> which literally falls apart, a term called osteonecrosis. A recent
> Library of Medicine Medline search yielded 165 articles on
> osteonecrosis of the jaw associated with bisphosphonate use, and most
> dentists have by now received warnings about this problem. Dr.
> Dimitrakopoulos from the Department of Oral and Maxillofacial Surgery,
> Aristotle University of Thessaloniki, Greece. reports in July 2006
> issue of Int J Oral Maxillofac Surg. 11 patients presenting with
> necrosis of the jaw, and he claims this to be a new complication of
> bisphosphonate therapy. He advises physicians to reconsider the merits
> of the rampant use of bisphosphonate drugs for osteoporosis.
>
> Osteonecrosis of the jaw is also a common finding in the rare genetic
> bone disease called, pycnodysostosis, which is what afflicted Toulouse
> Lautrec, the famous French Impressionist artist. By the way, Toulouse
> also suffered spontaneous mid femur fractures at the age of 12, just
> like the woman on the subway described above. His fractures failed to
> heal and Toulouse Lautrec only attained a height of 4 and a half feet.
>
> In conclusion, the bisphosphonate drugs for osteoporosis may have some
> short term benefits, however, adverse side effects of spontaneous
> fracture and osteonecrosis of the jaw should be mentioned when
> considering long term use. For a natural approach to osteoporosis
> prevention and treatment without drugs, see my web site:
> www .drdach,com .
>
> Jeffrey Dach
>
Hi Sammy: I thought Merck did this for convenience, but I would confirm that
with your dr or pharmacist. Fosamax plus D has 2,800 IU of D3 so it represents
a weeks worth of D at 400 IU's daily. I suppose it would be up to you or your
dr which way of taking it is easier, daily or weekly. You do need to know if
you are taking anything, or have a disorder that would deplete your system of D,
and a pharmacist could give you a list of those drugs/disorders, or it should be
listed on the Merck website. Also some feel that 400 daily IU's isn't enough D
for certain age groups so you could ask about that as well.
Pam
"keyboard" <keyboard@anonymousSpeech,com > wrote in message
news:1166737952.097865.8380@i12g2000cwa.googlegroups,com ...
>
> Sammy wrote:
>> I cannot find any information about the advantages of taking Fosamax with D.
>> I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>>
>> Is there some advantage to taking it with D that you have read about? I
>> take my Calcium with D, and I am trying to figure out is the only advantage
>> is convenience, I should not bother. It may not be especially easy to fine
>> Calcium with Magnisium and no D. Also I cannot even find out how much D is
>> in the Fosamax.
>>
>> My doctor said she would be happy to send me a new prescription, but does
>> not know if there is any advantage to switching.
>>
>> Sammy
>
> For people with the fragile bones of osteoporosis, Fosamax and Actonel
> were approved by the FDA about 11 years ago. Doctors wrote 22 million
> Fosamax prescriptions last year making 3.2 Billion dollars for the drug
> maker, Merck. Fosamax reduced fracture rates in the Fracture
> Intervention Trial for severe forms of osteoporosis, but for the milder
> form of osteoporosis (osteopenia), there was no benefit. These
> bisphosphonate drugs work their magic on bones by making the osteoclast
> bone cells nonfunctional. Although this allows new bone formation to
> proceed normally, the removal of old bone is halted resulting in
> increased bone density which shows up on DEXA bone scan.
>
> In spite of this increased bone density, Dr. Susan Ott, Associate
> Professor of Medicine, at the University of Washington in Seattle
> raised questions about the long term safety of bisphosphonates in her
> article in J Clin Endo Metab (Vol. 90, No. 3, 2005) . Although the
> drugs appear to have short term benefits, Dr. Ott speculates that after
> 5 years of use, there is severe suppression of bone formation with
> negative effects such as microdamage and brittleness of bone which may
> cause spontaneous fractures, an outcome quite the opposite of the
> intended use of Fosamax. Dr. Ott suggests stopping the drug within
> five years to avoid these adverse side effects.
>
> An example of this adverse side effect is described by Dr.
> Jennifer P. Schneider in the Jan 2006 issue of Geriatrics reporting on
> a 59-year old previously healthy woman on long-term Fosamax treatment.
> One morning, while the woman rode a subway train in New York City, the
> train jolted, and the woman shifted all her weight to one leg, felt a
> bone snap, fell to the floor with a spontaneous mid-femur fracture. In
> the months following, the mid-femur fracture failed to heal. Dr.
> Schneider speculates that the increased bone density from the
> bisphosphonate drug did not produce good bone quality. Instead she
> speculates that long term use of the drug caused microdamage and
> brittle bone formation resulting in the spontaneous mid femur fracture.
>
> Dr. Clarita V. Odvina, in the 2005 issue of J Clin Endo & Metab
> (Vol. 90, No. 3) reports on 9 patients who had spontanous fractures
> while on Fosamax. Five of the nine cases were spontaneous mid femur
> fractures with minimal trauma. Dr. Odvina raised the possibility that
> long-term Fosamax (alendronate) therapy could result in increased
> susceptibility to fractures, quite the opposite of its intended use.
>
> Another bone which shows weakening from bisphosphonates is the jaw bone
> which literally falls apart, a term called osteonecrosis. A recent
> Library of Medicine Medline search yielded 165 articles on
> osteonecrosis of the jaw associated with bisphosphonate use, and most
> dentists have by now received warnings about this problem. Dr.
> Dimitrakopoulos from the Department of Oral and Maxillofacial Surgery,
> Aristotle University of Thessaloniki, Greece. reports in July 2006
> issue of Int J Oral Maxillofac Surg. 11 patients presenting with
> necrosis of the jaw, and he claims this to be a new complication of
> bisphosphonate therapy. He advises physicians to reconsider the merits
> of the rampant use of bisphosphonate drugs for osteoporosis.
>
> Osteonecrosis of the jaw is also a common finding in the rare genetic
> bone disease called, pycnodysostosis, which is what afflicted Toulouse
> Lautrec, the famous French Impressionist artist. By the way, Toulouse
> also suffered spontaneous mid femur fractures at the age of 12, just
> like the woman on the subway described above. His fractures failed to
> heal and Toulouse Lautrec only attained a height of 4 and a half feet.
>
> In conclusion, the bisphosphonate drugs for osteoporosis may have some
> short term benefits, however, adverse side effects of spontaneous
> fracture and osteonecrosis of the jaw should be mentioned when
> considering long term use. For a natural approach to osteoporosis
> prevention and treatment without drugs, see my web site:
> www .drdach,com .
>
> Jeffrey Dach
>
Re: Fosamax with D
Pam wrote:
: Also some feel that 400 daily
: IU's isn't enough D for certain age groups so you could ask about
: that as well.
It isn't a question of age group only. The point is that the circulating
vitamin D (calcidiol aka 25(OH)D) levels have to be high enough to reduce
fracture risk. When the circulating vitamin D levels have been below 73
nmol/l no effect in preventing fractures have been observed. In practise
this means that many, probably most of people who have osteoporosis fall to
this category. Hence their is an urgent need to increase the vitamin D
intake to achive such calcidiol levels (>80 nmol/l) that they have a
positive effect on bone health.
--
Juhana
Pam wrote:
: Also some feel that 400 daily
: IU's isn't enough D for certain age groups so you could ask about
: that as well.
It isn't a question of age group only. The point is that the circulating
vitamin D (calcidiol aka 25(OH)D) levels have to be high enough to reduce
fracture risk. When the circulating vitamin D levels have been below 73
nmol/l no effect in preventing fractures have been observed. In practise
this means that many, probably most of people who have osteoporosis fall to
this category. Hence their is an urgent need to increase the vitamin D
intake to achive such calcidiol levels (>80 nmol/l) that they have a
positive effect on bone health.
--
Juhana
Re: Fosamax with D
Juhana Harju wrote:
: Pam wrote:
:
:: Also some feel that 400 daily
:: IU's isn't enough D for certain age groups so you could ask about
:: that as well.
:
: It isn't a question of age group only. The point is that the
: circulating vitamin D (calcidiol aka 25(OH)D) levels have to be high
: enough to reduce fracture risk. When the circulating vitamin D levels
: have been below 73 nmol/l no effect in preventing fractures have been
: observed. In practise this means that many, probably most of people
: who have osteoporosis fall to this category. Hence their is an urgent
: need to increase the vitamin D intake to achive such calcidiol levels
: (>80 nmol/l) that they have a positive effect on bone health.
This a study confirming the high prevalence of inadequate vitamin D intake.
J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24.
Prevalence of Vitamin D inadequacy among postmenopausal North American women
receiving osteoporosis therapy.
Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA,
Chen E, de Papp AE.
PURPOSE: To evaluate serum 25-hydroxyvitamin D [25(OH)D] concentrations and
factors related to vitamin D inadequacy in postmenopausal North American
women receiving therapy to treat or prevent osteoporosis. METHODS: Serum
25(OH)D and PTH were obtained in 1536 community-dwelling women between
November 2003 and March 2004. Multivariate logistic regression was used to
assess risk factors for suboptimal (<30 ng/ml) 25(OH)D. RESULTS: Ninety-two
percent of study subjects were Caucasian, with a mean age of 71 yr.
Thirty-five percent resided at or above latitude 42 degrees north, and 24%
resided less than 35 degrees north. Mean (sd) serum 25(OH)D was 30.4 (13.2)
ng/ml: serum 25(OH)D was less than 20 ng/ml in 18%; less than 25 ng/ml in
36%; and less than 30 ng/ml in 52%. Prevalence of suboptimal 25(OH)D was
significantly higher in subjects who took less than 400 vs. 400 IU/d or more
vitamin D. There was a significant negative correlation between serum PTH
concentrations and 25(OH)D. Risk factors related to vitamin D inadequacy
included age, race, body mass index, medications known to affect vitamin D
metabolism, vitamin D supplementation, exercise, education, and physician
counseling regarding vitamin D. CONCLUSIONS: More than half of North
American women receiving therapy to treat or prevent osteoporosis have
vitamin D inadequacy, underscoring the need for improved physician and
public education regarding optimization of vitamin D status in this
population. PMID: 15797954
http :// tinyurl,com /y33gzr
--
Juhana
Juhana Harju wrote:
: Pam wrote:
:
:: Also some feel that 400 daily
:: IU's isn't enough D for certain age groups so you could ask about
:: that as well.
:
: It isn't a question of age group only. The point is that the
: circulating vitamin D (calcidiol aka 25(OH)D) levels have to be high
: enough to reduce fracture risk. When the circulating vitamin D levels
: have been below 73 nmol/l no effect in preventing fractures have been
: observed. In practise this means that many, probably most of people
: who have osteoporosis fall to this category. Hence their is an urgent
: need to increase the vitamin D intake to achive such calcidiol levels
: (>80 nmol/l) that they have a positive effect on bone health.
This a study confirming the high prevalence of inadequate vitamin D intake.
J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24.
Prevalence of Vitamin D inadequacy among postmenopausal North American women
receiving osteoporosis therapy.
Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA,
Chen E, de Papp AE.
PURPOSE: To evaluate serum 25-hydroxyvitamin D [25(OH)D] concentrations and
factors related to vitamin D inadequacy in postmenopausal North American
women receiving therapy to treat or prevent osteoporosis. METHODS: Serum
25(OH)D and PTH were obtained in 1536 community-dwelling women between
November 2003 and March 2004. Multivariate logistic regression was used to
assess risk factors for suboptimal (<30 ng/ml) 25(OH)D. RESULTS: Ninety-two
percent of study subjects were Caucasian, with a mean age of 71 yr.
Thirty-five percent resided at or above latitude 42 degrees north, and 24%
resided less than 35 degrees north. Mean (sd) serum 25(OH)D was 30.4 (13.2)
ng/ml: serum 25(OH)D was less than 20 ng/ml in 18%; less than 25 ng/ml in
36%; and less than 30 ng/ml in 52%. Prevalence of suboptimal 25(OH)D was
significantly higher in subjects who took less than 400 vs. 400 IU/d or more
vitamin D. There was a significant negative correlation between serum PTH
concentrations and 25(OH)D. Risk factors related to vitamin D inadequacy
included age, race, body mass index, medications known to affect vitamin D
metabolism, vitamin D supplementation, exercise, education, and physician
counseling regarding vitamin D. CONCLUSIONS: More than half of North
American women receiving therapy to treat or prevent osteoporosis have
vitamin D inadequacy, underscoring the need for improved physician and
public education regarding optimization of vitamin D status in this
population. PMID: 15797954
http :// tinyurl,com /y33gzr
--
Juhana
Re: Fosamax with D
If I take Fosamax with Vitamin D, I am afraid that it will be more difficult
to determine how much I need throughout the day. Also, I don't understand
how Fosamax can be time released to automatically give me the medication
throughout the week (Boniva throughout the month), but Vitamin D can be
released throughout the week too?
I take Vitamin D three times a day with my Calcium, and if I take the extra
that is not provided by Fosamax when the time release of Fosamax is
released, then I will have overdosed at one time a day, and not had enough
at another time of time. If I control it morning, noon, and night, I may be
better off.
I cannot find any site that addresses the need for taking D with Fosamax.
Sammy
"Sammy" <rstevrock@cox,net > wrote in message
news:4nzih.17571$gj2.2069@newsfe23.lga...
>I cannot find any information about the advantages of taking Fosamax with
>D. I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>
> Is there some advantage to taking it with D that you have read about? I
> take my Calcium with D, and I am trying to figure out is the only
> advantage is convenience, I should not bother. It may not be especially
> easy to fine Calcium with Magnisium and no D. Also I cannot even find out
> how much D is in the Fosamax.
>
> My doctor said she would be happy to send me a new prescription, but does
> not know if there is any advantage to switching.
>
> Sammy
>
If I take Fosamax with Vitamin D, I am afraid that it will be more difficult
to determine how much I need throughout the day. Also, I don't understand
how Fosamax can be time released to automatically give me the medication
throughout the week (Boniva throughout the month), but Vitamin D can be
released throughout the week too?
I take Vitamin D three times a day with my Calcium, and if I take the extra
that is not provided by Fosamax when the time release of Fosamax is
released, then I will have overdosed at one time a day, and not had enough
at another time of time. If I control it morning, noon, and night, I may be
better off.
I cannot find any site that addresses the need for taking D with Fosamax.
Sammy
"Sammy" <rstevrock@cox,net > wrote in message
news:4nzih.17571$gj2.2069@newsfe23.lga...
>I cannot find any information about the advantages of taking Fosamax with
>D. I have gone to the Merck site, About,com , Webmd, and Cedars of Sinai.
>
> Is there some advantage to taking it with D that you have read about? I
> take my Calcium with D, and I am trying to figure out is the only
> advantage is convenience, I should not bother. It may not be especially
> easy to fine Calcium with Magnisium and no D. Also I cannot even find out
> how much D is in the Fosamax.
>
> My doctor said she would be happy to send me a new prescription, but does
> not know if there is any advantage to switching.
>
> Sammy
>
Re: Fosamax with D
Sammy wrote:
: If I take Fosamax with Vitamin D, I am afraid that it will be more
: difficult to determine how much I need throughout the day. Also, I
: don't understand how Fosamax can be time released to automatically
: give me the medication throughout the week (Boniva throughout the
: month), but Vitamin D can be released throughout the week too?
:
: I take Vitamin D three times a day with my Calcium, and if I take the
: extra that is not provided by Fosamax when the time release of
: Fosamax is released, then I will have overdosed at one time a day,
: and not had enough at another time of time. If I control it morning,
: noon, and night, I may be better off.
There will be no notable fluctuations in the vitamin D levels as the kidneys
regulate the release of calcitriol, the active form of vitamin D. No reason
for your worries.
--
Juhana
Sammy wrote:
: If I take Fosamax with Vitamin D, I am afraid that it will be more
: difficult to determine how much I need throughout the day. Also, I
: don't understand how Fosamax can be time released to automatically
: give me the medication throughout the week (Boniva throughout the
: month), but Vitamin D can be released throughout the week too?
:
: I take Vitamin D three times a day with my Calcium, and if I take the
: extra that is not provided by Fosamax when the time release of
: Fosamax is released, then I will have overdosed at one time a day,
: and not had enough at another time of time. If I control it morning,
: noon, and night, I may be better off.
There will be no notable fluctuations in the vitamin D levels as the kidneys
regulate the release of calcitriol, the active form of vitamin D. No reason
for your worries.
--
Juhana
